CABBAY HOLDINGS CORP.

MANAGMENTS'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

For the Six Months and Three Months Ended June 30, 2019

Overview

This MD&A has been prepared as of August 29, 2019 and the following information should be read in conjunction with the Issuer's un-audited financial statements for the three and six months ended June 30, 2019 together with the notes thereto. The Issuer's financial statements for the period have been prepared in accordance with International Financial Reporting Standards (IFRS).

This discussion contains forward-looking statements that involve certain risks and uncertainties. Statements regarding future events, expectations and beliefs of management and other statements that do not express historical facts are forward-looking statements. In this discussion, the words "believe", "may", "will", "estimate", "continue", "anticipate", "intend", "expect", "plan", "predict", "potential" and similar expressions, as they relate to the Issuer, its business and management, are intended to identify forward looking statements. The Issuer has based these forward-looking statements largely on its current expectations and projections about future events and financial trends affecting the financial condition of the business. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward looking statements are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Except as may be required by applicable law or regulation, the Issuer undertakes no obligation to update publicly or release any revisions to these forward looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events. Accordingly, readers should not place undue reliance on forward-looking statements. If the Issuer updates one or more forward-looking statements, no inference should be drawn that additional updates will be made with respect to those or other forward-looking statements. Additional information relating to the Issuer, is available by accessing the SEDAR website at www.sedar.com.

Business Overview and Strategy

Cabbay Holdings Corp. (the "**Issuer"** or **"Company"** or **"Cabbay**") was incorporated as a wholly owned subsidiary of Tower One Wireless Corp. ("**Tower One**") in order to facilitate a plan of arrangement with Tower One, a public company whose common shares trade on the CSE. As part of the Plan of Arrangement which closed on October 3, 2016, Tower One transferred its interest in the ForwoRx Agreement and $1,000 to the Issuer. As a result of the Plan of Arrangement, the Issuer became a reporting issuer in British Columbia. In connection with the Plan of Arrangement, $435,360 of indebtedness was assigned to and assumed by the Issuer. The Issuer recorded a financing fee of $435,359 as a result of the transaction. Also, in connection with the Arrangement during the fiscal year ended December 31, 2017 $5,929 of indebtedness was assigned to and assumed by the Issuer and fiscal year ended December 31, 2018 $4,179 of indebtedness was assigned to and assumed by the Issuer.

On closing of the Plan of Arrangement, the Issuer was a holding company with major holding being an asset purchase agreement with ForwoRx Therapeutics Inc. (the **"ForwoRx Agreement"**) regarding the purchase of therapies to treat fibrosis, erectile dysfunction and pulmonary arterial hypertension. The ForwoRx Agreement covers the lead compound for Fibrosis, PTL-202, a combination of already approved drugs which have well established safety profiles. PTL-202 has completed a phase 1 drug/ drug interaction clinical trial. In addition, the agreement covers the purchase of a sublingual formulation of sildenafil citrate for use as a treatment for erectile dysfunction and pulmonary arterial hypertension. Neither of these programs is currently being funded.

The ForwoRx Agreement was originally entered into between Tower One (formerly Pacific Therapeutics Ltd.) and ForwoRx (formerly Forge Therapeutics Inc.) on July 23, 2015 pursuant to which Tower One agreed to sell certain of its technology assets (the "**Assets**") to ForwoRx. In consideration, ForwoRx agreed to issue to Tower One 15,000,000 of ForwoRx shares (the "**ForwoRx Shares**"). Pursuant to the terms of the ForwoRx Agreement, subject to certain conditions, between the closing of the asset sale, which occurred on July 23, 2015, and the issuance of the ForwoRx Shares, ForwoRx is to pay to Tower One an annual maintenance fee of $50,000 until the ForwoRx Shares have been issued. Currently ForwoRx is in arrears $150,000 of these maintenance fees. If the ForwoRx Shares are not issued before July 23, 2018, Tower One may at any time prior to July 23, 2020 [the fifth anniversary of the Closing Date], provide notice to ForwoRx of its election to trigger the issuance of the ForwoRx Shares (in whole and not in part), in which case ForwoRx will issue the ForwoRx Shares to the Vendor within 10 business days of receipt of such notice. If ForwoRx has not issued the ForwoRx Shares to Tower One on or before July 23, 2020 [the fifth anniversary of the Closing Date], and Tower One has not earlier provided notice of its election to receive the ForwoRx Shares, ForwoRx is required to promptly transfer and assign the Assets back to Tower One, free and clear of all encumbrances other than permitted encumbrances. As at the date of this MD&A, the Issuer has not received any ForwoRx Shares.

From the completion of the Plan of Arrangement the Issuer has been engaged in improving its balance sheet and seeking additional business opportunities, primarily related to transitioning into a vertically integrated corporation cultivating cannabis, manufacturing concentrates and manufacturing cannabis infused edibles and other products for medical and recreational use.

On March 26, 2018, the Issuer incorporated a British Columbia corporation Alta-Sun Samson Holdings Corp. (Alta-Sun). Alta-Sun plans to pursue the licensing, construction and operation of a cannabis growing facility on Enoch FN lands. Alta-Sun is the operator of the Enoch Facility.

Overall Performance

The Issuer is focused on Cannabis production in Alberta, Canada in partnership with First Nations leaders and communities and the development of cannabis infused products. These partnerships will develop cannabis facilities and utilize low cost inputs into cannabis cultivation with the goal of being a low-cost producer in the cannabis industry.

The Issuer, through its subsidiaries and partnerships with indigenous peoples, will apply for a cannabis production licenses on First Nations lands in Alberta beginning with the Enoch Cree First Nation.

The issuer plans to build a 5 acre outdoor cannabis cultivation facility on land it has leased on the Enoch First Nation lands.

Corporate Highlights

During the six-month period ended, June 30, 2019 the Issuer accomplished the following:

- On March 15, 2019 the Issuer signed a series of lines of credit to provide a total of $1.2 million of working capital. The Issuer committed to issued 500,000 common shares to the lenders to pay administration fees of $125,000. *See Use of Funds and Material Contracts.*
- On March 31, 2019 the Issuer signed an amended lease for the 5 acres of land at the Enoch Cree Nation.
- On March 31, 2019 the Issuers board approved the issuance of 200,000 Shares to Andy Morin as a bonus for contracting to be the Issuers Master Grower.
- On April 26, 2019 the Issuers board approved the issuance of 40,000 shares at $0.25 per share for total proceeds of $10,000. 20,000 of these shares were issued to Doug Unwin the Issuers CEO for proceeds of $5,000.
- On April 26, 2019 the Issuers board approved the issuance of 50,000 shares at a deemed value of $0.25 per share for the settlement of $12,500 owed to Doug Unwin the Issuers CEO under his employment contract. On the same date the Issuers board approved the issuance of 63,000 shares at a deemed value of $0.25 per share for the settlement of $15,750 owed to a director, Mark van der Horst for services.
- On April 26, 2019 the Issuers board approved the issuance of 500,000 shares at a deemed value of $0.25 per share as administrative fees for $1,200,000 lines of credit, of this amount was 125,000 shares will be issued to Robert Charlton the Issuers CFO.
- On April 26, 2019 the Issuers board approved the issue of 627,000 shares at a deemed value of $0.25 per share to settle outstanding payables.
- On May 29, 2019 the Issuer, issued 252,000 common shares at a price or $0.25 per share for total proceeds of $63,000.
- The Issuer has applied to have its Common Shares listed on the CSE. The Issuer has paid the initial application fee of $3,500.

- Mr. Tom Neumann was appointed to the Issuer’s Board of Directors on August 12, 2019 and issued 20,000 options to purchase common shares for $0.25 for up to 5 years on August 14, 2019.

- On August 22, 2019 Mr. Mark van der Horst resigned from the Company’s board of Directors.

Selected Financial Information

The financial information reported here has been prepared in accordance with IFRS. The Issuer uses the Canadian dollar (CDN) as its reporting currency. Selected un-audited financial data for interim operations of the Issuer for the three months and six months ended June 30, 2019 and for the three months and six months ended June 30, 2018 and June 30, 2017 are presented:

Selected Statement of Operations Data

Period ended	Three Months Ended June 30, 2019	Three Months Ended June 30, 2018	Three Months Ended June 30, 2017	Six Months Ended June 30, 2019	Six Months Ended June 30, 2018	Six Months Ended June 30, 2017
Total revenues	$Nil	$Nil	$Nil	$Nil	$Nil	$Nil
Net Income / (Loss)	$(103,922)	$(164,588)	$(24,034)	$(287,155)	$(247,782)	$(26,152)
Basic Income/(loss) per share	$(0.01)	$(0.02)	$(0.01)	$(0.02)	$(0.03)	$(0.01)
Diluted loss per share (Unaudited)	$(0.01)	$(0.02)	(0.01)	$(0.02)	$(0.03)	$(0.01)
Weighted average shares	11,283,938	10,668,719	2,785,371	11,590,407	9,271,672	2,112,502

Selected Balance Sheet Data

As At	June 30, 2019	December 31, 2018
Cash & Equivalents	$14,056	$40,250
Current Assets	$196,583	$94,183
Total Assets	$521,099	$364,074
Current liabilities	$219,112	$167,932
Non-Current liabilities	$Nil	$Nil
Total liabilities	$219,112	$167,932
Working Capital / (deficit)	$(22,529)	$(73,749)

Comparison of the Quarters ending June 30, 2019, June 30, 2018 and June 30, 2017

Revenues

The Issuer does not expect to receive revenue if any from the cannabis operations on the Enoch Cree First Nations ('Enoch FN") land until the end of 2020.

During the period ended June 30, 2019 the Issuer continued its operations in cannabis cultivation. On May the 8th 2019 Health Canada (**HC**) announced changes to the license application procedure under the Cannabis Act. These changes were implemented because 70% of applications that have been reviewed by Health Canada and given a certificate of readiness to build, have never submitted an evidence package to continue the licensing process. Under the new procedure, an applicant must submit its evidence package within 10 days of submitting its application. In addition, the application must now include an applicant's business plan. Health Canada has introduced this change to reduce the number of applications it receives and improve service levels to applicants ready to grow. Once the Enoch Facility is completed an evidence package will be assembled for submission with the application and business plan.

Because HC has indicated that applications under this new procedure may have reviews and security checks done in parallel reducing the application timeline, consultants estimate the application time line may be reduced to 6 months from the time an application is accepted. Consultants have the opinion that only applications submitted before December 31, 2018 that were in the review stage in early 2019 have any advantage over applications submitted under the new rules in relation to when a license would be issued. The Issuer does not anticipate revenues from the cannabis operation for the foreseeable future.

The Issuer is a holding company and holds an agreement with ForwoRx Therapeutics Inc. ("ForwoRx") *(see Business Overview and Strategy*). Under this agreement ForwoRx is to pay to the Issuer $50,000 per year in maintenance fees. This fee for 2018, 2017 and 2016 has not been paid and the company will not recognize it as revenue until such time that management is confident of its payment. As at March 31, 2019 $150,000 is due from ForwoRx.

Expenses

For the three months ended June 30, 2019 expenses totaled $103,922 (June 30, 2018 - $164,588, June 30, 2017 - $24,034) For the period ended June 30, 2019 expenses increased in accounting and audit fees due to an increase in audit fees as the company ramped up operations, consulting expenses decreased by $31,289 due to a decrease in consulting fees related to acquiring suitable land in Alberta, to the Cannabis Act application and greenhouse design, legal fees decreased by $14,894 due to a decrease in the need for legal advice in the period, wages increase from $3,750 to $7,500 due to management salaries that were initiated half way thru the second quarter of 2018 were expensed for a whole quarter during the current period when compared to the three months ended June 30, 2017. During the three month period ended June 30, 2017 the Issuer had minimal expenses to maintain the companies reporting status and investigate future business opportunities. During the three month period ended June 30, 2018 the Issuer pursued its plan of developing a greenhouse to grow cannabis on Samson FN lands and prepared a preliminary prospectus for submission to the British Columbia Securities Commission, causing increased expenses when compared to the three month period ended June 30, 2017; Consulting fees increased from $6,300 to $73,099 as consultants were hired to provide assistance in finance, land acquisition, indigenous relations, ACMPR application, as well as greenhouse design and financial analysis and modeling; Interest and bank charges increased as the $56,000 non-interest bearing short term loan was converted to a long-term interest bearing loan with an interest rate of 1% per month, the principal is due September 30, 2019; management fees increased as the President and CEO became a fulltime employee and a new CFO was added to the management team; office and administration costs increased to reflect the Issuers increased activity in pursuing its business plan; an increase in financing activity caused an increase in filling fees; travel increased as the Issuers operation are now focused in Alberta away from the head office in Vancouver, BC.

During the three month period ended June 30, 2019 the issuer assumed debt of $Nil (June 30, 2018 $4,179,2017 - $5,929) in relation the plan of arrangement with Tower One. During the three month period ended June 30, 2019, the Issuer had a loss on the conversion of long term debt of $Nil (June 30, 2018 - $17,268, 2017 - $Nil). The loss for the period ended June 30 2018 is attributed to the unamortized discounts on long-term debt balances that were converted to common shares. During the period ended June 30, 2018, Long-term debts totaling $95,000 were converted to 380,000 common shares. The $4,063 loss on repayment of long-term debt in the period ended June 30, 2018 relates to the unamortized discount on a long-term debt balance due to a related party that was paid off early.

Research & Development Expense

The company does not incur any expense associated with research and development under the asset purchase agreement with ForwoRx Therapeutics Inc.

General and Administrative Expenses

General and administrative costs consist primarily of consulting fees, management fees, accounting costs and other professional and administrative costs associated with maintenance of the Issuer's reporting status and general corporate activities such as pursuing the operations of the 5 acre outdoor cannabis grow out at the Encoh Cree Nation.

The General and administrative costs for the 3 month period ended June 30, 2019 was $103,922 (June 30, 2018 - $139,078, June 30, 2017 - $18,105. For additional discussion of the expenses please *see "Expenses"*.

Intellectual Property and Intangible Assets

The company has no costs associated with the maintenance of patents or intellectual property under the asset purchase agreement with ForwoRx Therapeutics Inc.

Interest Expense/(Income)

The interest expense in the six month period ended June 30, 2019 was $3,360 (June 30, 2018 - $3,360, June 30, 2017, $Nil). On September 12, 2017, the Company signed a debt assumption agreement which resulted in reclassification of a loan totaling $56,000 as long-term debt. The debt is now due on September 30, 2019 and accrues interest at 1% per month, payable quarterly. Interest expense for the six month period ended June 30, 2019 was $3,360. Interest accrued at June 30, 2019, is $2,016 (June 30, 2018 - $2,016, December 31, 2017: $2,016)

Profits

At this time, the Issuer is not anticipating profit from operations. The Issuer will report an annual deficit and quarterly deficit and will rely on its ability to obtain equity or debt financing and maintenance fees from the Asset Purchase Agreement to fund on-going operations. For information concerning the business of the Issuer, please see "*Business Overview and Strategy*".

Stock Based Compensation

For the 3 month period ended June 30, 2019 stock based compensation was $Nil (June 30, 2018,-Nil, June 30, 2017, $Nil).

Selected Quarterly Information

	Three Months Ended June 30, 2019	Three Months Ended March 31, 2019	Three Months Ended December 31, 2018	Three Months Ended September 30, 2018	Three Months Ended June 30, 2018	Three Months Ended March 31, 2018	Three Months Ended December 31, 2017	Three Months Ended September 30, 2017
	$	$	$		$	$	$	$
Total Revenues	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
Net Income (Loss)	(103,922)	(183,233)	(138,160)	(106,306)	(164,588)	(83,193)	(85,462)	(105,869)
Income (Loss) per Share basic and diluted	(0.01)	(0.02)	(0.01)	(0.01)	(0.02)	(0.01)	(0.01)	(0.02)
Cash	14,056	6,999	40,250	234,471	383,172	119,806	49,752	111,994
Total Assets	521,099	367,833	364,074	456,384	503,290	147,574	54,414	115,662
Non-Current Liabilities	Nil	Nil	Nil	Nil	56,000	154,059	151,203	132,642

Liquidity and Capital Resources

At June 30, 2019, the Issuer had cash and cash equivalents of $14,056 (June 30, 2018- $383,172) and working capital of ($22,529), (June 30, 2018 $427,395). Working capital improved by $51,220 when compared to the year ended December 31, 2018 ($73,749). This improvement was mostly due to an increase in prepaid expenses. Working capital is defined as current assets less current liabilities.

The Issuer's Cash flows from financing activities for the six months ended June 30, 2019 consisted of the issuance of 292,000 common shares for proceeds of $73,000, share subscriptions received of $10,000 and the settlement of $82,233 in liabilities with related parties.

Cash utilized in operating activities during the six months ended June 30, 2019 was $144,162 (June 30, 2018 - $320,196, June 30, 2017 - $26,541). The decrease in cash utilized in operations was mainly due to an increase in the finance fee paid in shares related to the lines of credit for the six month period ending June 30, 2019 of $125,000 (June 30, 2018 - $Nil, June 30, 2017- $Nil). During the six month period ended June 30, 2019 the issuer assumed debt of $Nil (June 30, 2018 - $4,179, June 30 2017 - $5,929) in relation to the plan of arrangement with Tower One. During the six month period ended June 30, 2019, the Issuer had a loss on the conversion of long term debt of $Nil (June 30, 2018 - $17,268, June 30, 2017 - $Nil). This loss is attributed to the unamortized discounts on long-term debt balances that were converted to common shares. Long-term debts totaling $95,000 were converted to 380,000 common shares during the six months ended June 30, 2018. The $4,063 loss on repayment of long-term debt during the six months ended June 30, 2018 relates to the unamortized discount on a long-term debt balance due to a related party that was paid off early (June 30, 2017 - $Nil).

At June 30, 2019 share capital was $1,568,675 comprised of 12,619,340 issued and outstanding Common Share (December 31, 2018: $1,184,675 comprised of 11,083,340 shares).

Warrant and Option Reserves at June 30, 2019 was $154,116 unchanged from December 31, 2018.

As a result of the net loss for the six months ended June 30, 2019 of $103,922 the deficit at June 30, 2019 increased to $1,430,804 from $1,143,649 for the year ended December 31, 2018.

Total equity improved from $196,142 at December 31, 2018 to $301,987 at June 30, 2018.

At present, the Issuer's operations do not generate cash inflows and its financial success after June 30, 2019 is dependent on Issuers ability to generate revenues from its cannabis operations and the asset purchase agreement with ForwoRx Therapeutics Inc. Neither of these operations may ever generate any revenues for the Issuer.

In order to finance the Issuer's future development plans, administrative and overhead expenses in the coming years the Issuer may raise money through equity sales. Many factors influence the Issuer's ability to raise funds, including the Issuer's track record, and the experience and calibre of its management. Actual funding requirements may vary from those planned due to a number of factors, including the progress of the Issuer's Cannabis Act application, issuance of permits and licenses from governments, approval from first nations band councils, construction of facilities, the Issuers ability to grow and sell cannabis profitably and research activities at ForwoRx Therapeutics Inc. Management believes it will be able to raise equity capital as required in the long term, but recognizes there will be risks involved that may be beyond their control. Should those risks fully materialize, it may not be able to raise adequate funds to continue its operations.

Off Balance Sheet Arrangements

There are currently no off -balance sheet arrangements which could have an effect on current or future results or operations or the financial condition of the Company.

Transactions with related parties are as follows:

	June 30, 2019	June 30, 2018
Accounting fees to a Company controlled by a director	$ 9,000	$ 9,500
Consulting fees to a Company controlled by a director	6,000	2,000
Consulting fees to a Company controlled by a director	30,000	43,424
Management fees to the CEO and director	48,000	46,850
Wages to the CEO and director	15,000	3,750
Finance fee to a director (Note 11)	31,250	-
	$ 139,250	$ 105,524

Balance due to the CEO and director:

- As of June 30, 2019, the Company has $23,406 (December 31, 2018: $7,971) owing to the CEO and director of the Company. The balance has no set terms of repayment and does not bear interest.
- On April 26, 2019 the CEO and director converted $12,500 of debt into 50,000 shares at a price of $0.25 per share.
- On September 20, 2017 the CEO and director signed an agreement which resulted in reclassification of $100,000 of payables as long-term. The debt was due January 1, 2020 and did not bear interest. The initial fair value of the long-term debt was recorded at $76,642 using a discount rate of 12%. An interest benefit of $23,358 was recorded as an equity reserve upon reclassification.
- On February 23, 2018 the CEO and director assigned $50,000 of the long-term debt to arm's-length parties (Note 7).
- On April 12, 2018 $25,000 of the long-term debt was converted to units at a conversion rate of $0.25 per unit pursuant to a private placement (Note 10). The Company recorded a loss $4,673 on the conversion related to the unamortized discount.
- During the year ended December 31, 2018 the remaining long-term debt balance was paid off. The Company recorded a loss $4,063 on repayment relating to the unamortized discount.

Balance due to a family member of the CEO and director:

- On December 18, 2017 the CEO and director assigned $20,000 of debt to this individual, which resulted in reclassification of the payable as long-term. The debt was due on September 30, 2019 and did not bear interest. The initial fair value of the debt was recorded at $16,262 using a discount rate of 12%. An interest benefit of $3,738 was recorded as an equity reserve upon reclassification.
- On April 12, 2018 the entire balance was converted to 80,000 units at a conversion rate of $0.25 per unit pursuant to a private placement (Note 10). The Company recorded a loss $3,250 on the conversion relating to the unamortized discount on the long-term debt.

Other balances due to related parties:

- As of June 30, 2019, the Company has $20,282 (December 31, 2018: $4,482) owing to a Company controlled by a director. The amount does not bear interest and has no set terms of repayment. On April 26, 2019 the director converted $31,250 of debt relating to the finance fee on the line of credit into 125,000 shares (Note 11).

- As of June 30, 2019, the Company has a balance of $22,749 (December 31, 2018: $6,999 included in accounts payable and accrued liabilities) owing to a Company controlled by a director. The amount does not bear interest and has no set terms of repayment. On April 26, 2019, $15,750 of the balance was converted to 63,000 shares at a price of $0.25 per share.
- As June 30, 2019, the Company has $100 (December 31, 2018: $100) owing to a former director of the Company. The amount does not bear interest and has no set terms of repayment.

Subsequent Events

Subsequent to June 30, 2019

- On July 3, 2019 the issuer, Issued 160,000 common shares at a price or $0.25 per share for total proceeds of $40,000.

- Mr. Tom Neumann was appointed to the Issuer's Board of Directors on August 12, 2019 and issued 20,000 options to purchase common shares for $0.25 for up to 5 years on August 14, 2019.

- On August 22, 2019 Mr. Mark van der Horst resigned from the Company's board of Directors.

Proposed Transactions

As at the date of this Management Discussion and Analysis there are no transactions currently contemplated by the Issuer, other than the proposed greenhouse facility on the Samson First Nations land. See "*Business Overview and Strategy"*

Financial Instruments and Other Instruments

The Issuer's financial instruments consist of cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and amounts due to shareholders. Unless otherwise noted, it is management's opinion that the Issuer is not exposed to significant interest, currency or credit risks arising from financial instruments. The fair value of cash and cash equivalents, amounts receivable and accounts payable and accrued liabilities approximates their carrying value due to their short-term maturity or capacity for prompt liquidation.

Disclosure of Outstanding Share Data

As at June 30, 2019, the Issuer had an unlimited number of authorized common shares with 12,619,340 common shares issued and outstanding.

As at June 30, 2019 the issuer had 1,005,000 options outstanding. Each option has an exercise price as detailed in the table below.

As at June 30, 2019 the Issuer had 1,976,691 warrants outstanding. Pursuant to the private placement on April 12, 2017, the Company issued 1,614,358 share purchase warrants. Each whole warrant entitles the holder to purchase one common share at a price of $0.35 per share for a period of two years from the date of issue. The warrants were assigned a value of $39,045 using the residual value method.

The following table shows the details for the outstanding warrants and options:

Description of Security (include conversion / exercise terms, including conversion / exercise price)	Number of convertible / exchangeable securities outstanding	Number of listed securities issuable upon conversion / exercise
Warrants 1 whole warrant exercisable at $3.00 up until October 8, 2019	72,000	72,000
Warrants 1 whole warrant exercisable at $3.00 up until October 18, 2019	66,000	66,000
Warrants 1 whole warrant exercisable at $3.00 up until November 5, 2019	224,333	224,333
Warrants 1 whole warrant	1,614,358	1,614,358

exercisable at $0.35 up until April 12, 2020		
Options expiring October 31, 2021 with an exercise price of $0.10	100,000	100,000
Options expiring January 18, 2022 with an exercise price of $0.10	25,000	25,000
Options expiring July 10, 2022 with an exercise price of $0.10	340,000	340,000
Options expiring September 21, 2022 with an exercise price of $0.10	220,000	220,000
Options expiring October 18, 2023 with an exercise price of $0.25	320,000	320,000